NASDAQ · MAZE
Maze Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MAZE: Nov 5, 2026
Maze Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.78. The reported EPS for the same quarter last year was $-0.66.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.78 | $-0.68 | $-0.84 | 5 |
| Dec 2026 | $-0.80 | $-0.71 | $-0.88 | 5 |
| Mar 2027 | $-0.72 | $-0.65 | $-0.84 | 4 |
| Jun 2027 | $-0.72 | $-0.61 | $-0.87 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · The Motley Fool · RTTNews- Zacks · Oct 19, 11:00 AM EDTWhat Makes Maze Therapeutics, Inc. (MAZE) a New Buy StockMaze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Oct 19, 8:55 AM EDTHow Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock
- MarketBeat · Oct 5, 10:55 AM EDT3 Small-Cap Stocks With Catalysts That Could Put Them in the SpotlightSmall-cap companies are accustomed to living in the shadow of mega-cap tech firms, but there are signs that the market backdrop could be changing for some of these companies. Investors have been looking beyond the Magnificent Seven for growth opportunities, and smaller companies
- The Motley Fool · Sep 11, 4:07 PM EDTMaze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000Chief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026.
- RTTNews · Aug 12, 11:22 AM EDTMaze Posts Wider Loss In Q2; Expects Phase 2 CIPheR Data For MZE782 In FY27(RTTNews) – Maze Therapeutics, Inc. (MAZE) a clinical-stage biotech company, announced financial results for the second quarter, highlighting wider loss than a year ago, driven by higher operating expenses.
- Zacks · Jul 21, 9:55 AM EDTCan Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- The Motley Fool · Jun 29, 9:06 AM EDTWhat Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?CEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026.
- The Motley Fool · Jun 5, 3:00 PM EDTMaze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?CEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share.
- The Motley Fool · May 17, 3:13 PM EDTMaze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in SharesHighVista Strategies sold 70,503 shares of Maze Therapeutics in the first quarter; the estimated trade value was $3.11 million.
- Zacks · May 12, 5:15 PM EDTMaze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue EstimatesMaze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · May 7, 8:32 AM EDTMaze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 FinancialsChief Strategy and Business Officer Atul Dandekar exercised and sold 7,500 shares of common stock for a transaction value of ~$190,000 on April 29, 2026.
- RTTNews · Apr 22, 1:16 AM EDTMaze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering(RTTNews) – Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Maze Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.